Research graph
References from Service delivery interventions for lipid testing and lipid-lowering therapy for primary and secondary prevention of cardiovascular disease in adults. Local targets link to admitted publications; unresolved targets remain external evidence.
Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990-2023
10.1016/j.jacc.2025.08.015 · 2025 · External reference
Unresolved reference
External reference
Atherosclerotic cardiovascular disease: a review of initiators and protective factors
10.1007/s10787-015-0255-y · 2016 · External reference
World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions
10.1016/s2214-109x(19)30318-3 · 2019 · External reference
2025 focused update of the 2019 ESC/EAS guidelines for the management of dyslipidaemias
10.1093/eurheartj/ehaf190 · 2025 · External reference
Relationship between hyperlipidemia, cardiovascular disease and stroke: a systematic review
10.2174/1573403x16999201210200342 · 2021 · External reference
Dyslipidemia and the current state of cardiovascular disease: epidemiology, risk factors, and effect of lipid lowering
10.1016/j.cjca.2024.04.017 · 2024 · External reference
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study
10.1016/s0140-6736(04)17018-9 · 2004 · External reference
Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study
10.1016/s0140-6736(19)32008-2 · 2020 · External reference
Barriers to accessibility of medicines for hyperlipidemia in low- and middle-income countries
10.1371/journal.pgph.0002905 · 2024 · External reference
Point-of-care testing for the analysis of lipid panels: primary care diagnostic technology update
10.3399/bjgp12x630241 · 2012 · External reference
Point of care testing
10.1136/bmj.322.7297.1285 · 2001 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
The impact of a point-of-care testing device on CVD risk assessment completion in New Zealand primary-care practice: a cluster randomised controlled trial and qualitative investigation
10.1371/journal.pone.0174504 · 2017 · External reference
Point-of-care testing to promote cardiovascular disease risk assessment: a proof of concept study
10.1016/j.pmedr.2017.05.016 · 2017 · External reference
Pharmacist-led Interventions to improve medication adherence among patients with multimorbidity: a scoping review
10.2147/ppa.s542881 · 2025 · External reference
Updated guidelines for the management of dyslipidemia and the prevention of cardiovascular disease in adults by pharmacists
10.1177/17151635231164989 · 2023 · External reference
Can we trust published evidence on point-of-care tests for cholesterol? A rapid review
10.1136/bmjopen-2023-080726 · 2025 · External reference
Advances in treatment of dyslipidemia
10.3390/ijms241713288 · 2023 · External reference
Unresolved reference
External reference
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
10.1161/cir.0000000000000625 · 2019 · External reference
Multidisciplinary teams in clinical lipidology and cardiometabolic care: a National Lipid Association expert clinical review
10.1016/j.jacl.2025.05.002 · 2025 · External reference
2025 ACC/AHA clinical practice guidelines core principles and development process: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
10.1016/j.jacc.2025.06.013 · 2025 · External reference
Nonadherence to lipid-lowering therapy and strategies to improve adherence in patients with atherosclerotic cardiovascular disease
10.1002/clc.23935 · 2023 · External reference
Unmet need for hypercholesterolemia care in 35 low- and middle-income countries: a cross-sectional study of nationally representative surveys
10.1371/journal.pmed.1003841 · 2021 · External reference
Exploring barriers and facilitators of primary care physicians towards optimising statin therapy in patients with hyperlipidaemia in the very high-risk group: a qualitative study in Singapore
10.1136/bmjopen-2023-073125 · 2023 · External reference
Measuring public preferences for statin therapy using the smallest worthwhile difference
10.1001/jamainternmed.2025.7958 · 2026 · External reference
Barriers and facilitators to using statins: a qualitative study with patients and family physicians
10.1016/j.cjco.2020.07.002 · 2020 · External reference
Low awareness of lipid disorders amongst individuals despite their high prevalence
10.1007/s11845-025-03973-w · 2025 · External reference
Global guidance for dyslipidaemia management in adults: a scoping review
10.5334/gh.1506 · 2025 · External reference
A systematic review of the evidence for pharmacist care of patients with dyslipidemia
10.1002/j.1875-9114.2012.01022.x · 2012 · External reference
Sensitivity of patient outcomes to pharmacist interventions. Part III: systematic review and meta-analysis in hyperlipidemia management
10.1345/aph.1k618 · 2008 · External reference
Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials
10.1016/j.atherosclerosis.2007.01.023 · 2008 · External reference
Effects of age, gender and statin dose on lipid levels: results from the VOYAGER meta-analysis database
10.1016/j.atherosclerosis.2017.08.014 · 2017 · External reference
Metabolic syndrome predicts cardiovascular risk and mortality in familial hypercholesterolemia
10.1016/j.jacl.2023.03.008 · 2023 · External reference
Management of dyslipidemia in HIV-infected patients
10.2217/clp.11.25 · 2011 · External reference
Lipoprotein metabolism, dyslipidemia, and lipid-lowering therapy in women: a comprehensive review
10.3390/ph17070913 · 2024 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
10.1136/bmj.n71 · 2021 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
POCT accreditation ISO 15189 and ISO 22870: making the point
2021 · External reference
Unresolved reference
External reference
Translating the Cochrane EMBASE RCT filter from the Ovid interface to Embase.com: a case study
10.1111/hir.12269 · 2019 · External reference
Development and validation of study filters for identifying controlled non-randomized studies in PubMed and Ovid MEDLINE
10.1002/jrsm.1425 · 2020 · External reference
PRESS Peer Review of Electronic Search Strategies: 2015 guideline statement
10.1016/j.jclinepi.2016.01.021 · 2016 · External reference
Unresolved reference
External reference
An evaluation of Cochrane Crowd found that crowdsourcing produced accurate results in identifying randomized trials
10.1016/j.jclinepi.2021.01.006 · 2021 · External reference
Machine learning reduces workload with minimal risk of missing studies: development and evaluation of an RCT classifier for Cochrane reviews
10.1016/j.jclinepi.2020.11.003 · 2020 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
RoB 2: a revised tool for assessing risk of bias in randomised trials
10.1136/bmj.l4898 · 2019 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study
10.1136/bmj.j2099 · 2017 · External reference
Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score
10.1001/jama.297.6.611 · 2007 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline
10.1136/bmj.l6890 · 2020 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions
10.1016/j.jclinepi.2019.10.014 · 2020 · External reference
Applying an equity lens to interventions: using PROGRESS ensures consideration of socially stratifying factors to illuminate inequities in health
10.1016/j.jclinepi.2013.08.005 · 2014 · External reference
Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score
10.1001/jama.297.6.611 · ExternalCitation · doi-reference
Measuring public preferences for statin therapy using the smallest worthwhile difference
10.1001/jamainternmed.2025.7958 · ExternalCitation · doi-reference
Nonadherence to lipid-lowering therapy and strategies to improve adherence in patients with atherosclerotic cardiovascular disease
10.1002/clc.23935 · ExternalCitation · doi-reference
A systematic review of the evidence for pharmacist care of patients with dyslipidemia
10.1002/j.1875-9114.2012.01022.x · ExternalCitation · doi-reference
Development and validation of study filters for identifying controlled non-randomized studies in PubMed and Ovid MEDLINE
10.1002/jrsm.1425 · ExternalCitation · doi-reference
Atherosclerotic cardiovascular disease: a review of initiators and protective factors
10.1007/s10787-015-0255-y · ExternalCitation · doi-reference
Low awareness of lipid disorders amongst individuals despite their high prevalence
10.1007/s11845-025-03973-w · ExternalCitation · doi-reference
Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials
10.1016/j.atherosclerosis.2007.01.023 · ExternalCitation · doi-reference
Effects of age, gender and statin dose on lipid levels: results from the VOYAGER meta-analysis database
10.1016/j.atherosclerosis.2017.08.014 · ExternalCitation · doi-reference
Dyslipidemia and the current state of cardiovascular disease: epidemiology, risk factors, and effect of lipid lowering
10.1016/j.cjca.2024.04.017 · ExternalCitation · doi-reference
Barriers and facilitators to using statins: a qualitative study with patients and family physicians
10.1016/j.cjco.2020.07.002 · ExternalCitation · doi-reference
2025 ACC/AHA clinical practice guidelines core principles and development process: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
10.1016/j.jacc.2025.06.013 · ExternalCitation · doi-reference
Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990-2023
10.1016/j.jacc.2025.08.015 · ExternalCitation · doi-reference
Metabolic syndrome predicts cardiovascular risk and mortality in familial hypercholesterolemia
10.1016/j.jacl.2023.03.008 · ExternalCitation · doi-reference
Multidisciplinary teams in clinical lipidology and cardiometabolic care: a National Lipid Association expert clinical review
10.1016/j.jacl.2025.05.002 · ExternalCitation · doi-reference
Applying an equity lens to interventions: using PROGRESS ensures consideration of socially stratifying factors to illuminate inequities in health
10.1016/j.jclinepi.2013.08.005 · ExternalCitation · doi-reference
PRESS Peer Review of Electronic Search Strategies: 2015 guideline statement
10.1016/j.jclinepi.2016.01.021 · ExternalCitation · doi-reference
GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions
10.1016/j.jclinepi.2019.10.014 · ExternalCitation · doi-reference
Machine learning reduces workload with minimal risk of missing studies: development and evaluation of an RCT classifier for Cochrane reviews
10.1016/j.jclinepi.2020.11.003 · ExternalCitation · doi-reference
An evaluation of Cochrane Crowd found that crowdsourcing produced accurate results in identifying randomized trials
10.1016/j.jclinepi.2021.01.006 · ExternalCitation · doi-reference
Point-of-care testing to promote cardiovascular disease risk assessment: a proof of concept study
10.1016/j.pmedr.2017.05.016 · ExternalCitation · doi-reference
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study
10.1016/s0140-6736(04)17018-9 · ExternalCitation · doi-reference
Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study
10.1016/s0140-6736(19)32008-2 · ExternalCitation · doi-reference
World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions
10.1016/s2214-109x(19)30318-3 · ExternalCitation · doi-reference
2025 focused update of the 2019 ESC/EAS guidelines for the management of dyslipidaemias
10.1093/eurheartj/ehaf190 · ExternalCitation · doi-reference
Translating the Cochrane EMBASE RCT filter from the Ovid interface to Embase.com: a case study
10.1111/hir.12269 · ExternalCitation · doi-reference
Point of care testing
10.1136/bmj.322.7297.1285 · ExternalCitation · doi-reference
Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study
10.1136/bmj.j2099 · ExternalCitation · doi-reference
RoB 2: a revised tool for assessing risk of bias in randomised trials
10.1136/bmj.l4898 · ExternalCitation · doi-reference
Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline
10.1136/bmj.l6890 · ExternalCitation · doi-reference
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
10.1136/bmj.n71 · ExternalCitation · doi-reference
Exploring barriers and facilitators of primary care physicians towards optimising statin therapy in patients with hyperlipidaemia in the very high-risk group: a qualitative study in Singapore
10.1136/bmjopen-2023-073125 · ExternalCitation · doi-reference
Can we trust published evidence on point-of-care tests for cholesterol? A rapid review
10.1136/bmjopen-2023-080726 · ExternalCitation · doi-reference
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
10.1161/cir.0000000000000625 · ExternalCitation · doi-reference
Updated guidelines for the management of dyslipidemia and the prevention of cardiovascular disease in adults by pharmacists
10.1177/17151635231164989 · ExternalCitation · doi-reference
Sensitivity of patient outcomes to pharmacist interventions. Part III: systematic review and meta-analysis in hyperlipidemia management
10.1345/aph.1k618 · ExternalCitation · doi-reference
Barriers to accessibility of medicines for hyperlipidemia in low- and middle-income countries
10.1371/journal.pgph.0002905 · ExternalCitation · doi-reference
Unmet need for hypercholesterolemia care in 35 low- and middle-income countries: a cross-sectional study of nationally representative surveys
10.1371/journal.pmed.1003841 · ExternalCitation · doi-reference
The impact of a point-of-care testing device on CVD risk assessment completion in New Zealand primary-care practice: a cluster randomised controlled trial and qualitative investigation
10.1371/journal.pone.0174504 · ExternalCitation · doi-reference
Pharmacist-led Interventions to improve medication adherence among patients with multimorbidity: a scoping review
10.2147/ppa.s542881 · ExternalCitation · doi-reference
Relationship between hyperlipidemia, cardiovascular disease and stroke: a systematic review
10.2174/1573403x16999201210200342 · ExternalCitation · doi-reference
Management of dyslipidemia in HIV-infected patients
10.2217/clp.11.25 · ExternalCitation · doi-reference
Advances in treatment of dyslipidemia
10.3390/ijms241713288 · ExternalCitation · doi-reference
Lipoprotein metabolism, dyslipidemia, and lipid-lowering therapy in women: a comprehensive review
10.3390/ph17070913 · ExternalCitation · doi-reference
Point-of-care testing for the analysis of lipid panels: primary care diagnostic technology update
10.3399/bjgp12x630241 · ExternalCitation · doi-reference
Global guidance for dyslipidaemia management in adults: a scoping review
10.5334/gh.1506 · ExternalCitation · doi-reference
